Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
ELVN
#1719
Enliven Therapeutics, Inc. Common Stock
29.690
0
+2.63%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+2.63%
Monthly Change
+13.58%
6 month change
+43.71%
Year Change
+43.71%
Previous Close
28.930
0
Open
29.700
0
Bid
Ask
Low
29.690
0
High
29.700
0
Volume
140
Markets
US Stock Market
Healthcare
ELVN
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
News
Heyman, direttore di Enliven Therapeutics, vende azioni per 32.000$
Heyman, Enliven Therapeutics director, sells $32k in stock
Lyssikatos, CSO di Enliven Therapeutics, vende azioni per $145k
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares
Lyssikatos, CSO di Enliven Therapeutics, vende azioni ELVN per 535.000$
Lyssikatos, Enliven Therapeutics CSO, sells $535k in ELVN stock
Il direttore di Enliven Therapeutics Heyman vende azioni per $32.901
Enliven Therapeutics director Heyman sells $32,901 in stock
Anish Patel, COO of Enliven Therapeutics, sells $1.35m in ELVN
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious
Il CSO di Enliven Therapeutics Lyssikatos vende azioni per 3,47 milioni di dollari
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares